Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
The First Report of Iranian Registry of Patients With Spinal Muscular Atrophy Publisher Pubmed



Mansouri V1 ; Heidari M2 ; Bemanalizadeh M2, 3 ; Azizimalamiri R4 ; Nafissi S5 ; Akbari MG6 ; Barzegar M7 ; Moayedi AR8 ; Badv RS2 ; Mohamadi M2 ; Tavasoli AR2 ; Amirsalari S9 ; Khajeh A10 ; Inaloo S11 Show All Authors
Authors
  1. Mansouri V1
  2. Heidari M2
  3. Bemanalizadeh M2, 3
  4. Azizimalamiri R4
  5. Nafissi S5
  6. Akbari MG6
  7. Barzegar M7
  8. Moayedi AR8
  9. Badv RS2
  10. Mohamadi M2
  11. Tavasoli AR2
  12. Amirsalari S9
  13. Khajeh A10
  14. Inaloo S11
  15. Fatehi F5
  16. Hosseinpour S12
  17. Babaei M13
  18. Hosseini SA14
  19. Mahdi Hosseiny SM15
  20. Fayyazi A15
  21. Hosseini F15
  22. Toosi MB16
  23. Khosroshahi N17
  24. Ghabeli H2
  25. Biglari HN18
  26. Kakhki SK17
  27. Mirlohi SH19
  28. Bidabadi E20
  29. Mohammadi B21
  30. Omrani A22
  31. Sedighi M23
  32. Vafaeeshahi M24
  33. Rasulinezhad M24
  34. Hoseini SM25
  35. Movahedinia M26
  36. Rezaei Z2
  37. Karimi P27
  38. Farshadmoghadam H28
  39. Anvari S29
  40. Yaghini O3
  41. Nasiri J3
  42. Zamani G2
  43. Ashrafi MR2, 30

Source: Journal of Neuromuscular Diseases Published:2023


Abstract

Background: Insufficient amounts of survival motor neuron protein is leading to one of the most disabling neuromuscular diseases, spinal muscular atrophy (SMA). Before the current study, the detailed characteristics of Iranian patients with SMA had not been determined. Objective: To describe the key demographic, clinical, and genetic characteristics of patients with SMA registered in the Iranian Registry of SMA (IRSMA). Methods: IRSMA has been established since 2018, and the demographic, clinical, and genetic characteristics of patients with SMA were recorded according to the methods of treat neuromuscular disease (TREAT-NMD) project. Results: By October 1, 2022, 781 patients with 5q SMA were registered. Of them, 164 patients died, the majority of them had SMA type 1 and died during the first 20 months of life. The median survival of patients with type 1 SMA was 23 months. The consanguinity rate in 617 alive patients was 52.4%, while merely 24.8% of them had a positive family history. The most common type of SMA in live patients was type 3. Morbidities were defined as having scoliosis (44.1%), wheelchair dependency (36.8%), tube feeding (8.1%), and requiring mechanical ventilation (9.9%). Most of the registered patients had a homozygous deletion of SMN1, while the frequency of patients with higher copy numbers of SMN2, was less in more severe types of the disease. Earlier onset of the disease was significantly seen in patients with lower copy numbers of SMN2. The neuronal apoptosis inhibitory protein (NAIP) gene deletion was associated with a higher incidence of more severe types of SMA, higher dependency on ventilators, tube feeding, and earlier onset of the disease. Conclusions: The IRSMA is the first established Iranian nationwide registry of patients with SMA. Using this registry, decision-makers, researchers, and practitioners can precisely understand the epidemiology, characteristics, and genetics of patients with SMA in Iran. © 2023 - IOS Press. All rights reserved.